Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy

Onkologie

Volumn 36, Issue 3, 2013, Pages 123-125

  Hartlapp, Ingo ^a   Müller, Justus ^a   Kenn, Werner ^a   Steger, Ulrich ^a   Isbert, Christoph ^a   Scheurlen, Michael ^a   Germer, Christoph Thomas ^a   Einsele, Hermann ^a   Kunzmann, Volker ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Complete pathological remission; FOLFIRINOX; nab Paclitaxel; Neoadjuvant chemotherapy; Pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL;

ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURGERY; CASE REPORT; ENDOSCOPIC ECHOGRAPHY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREATICODUODENECTOMY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PANCREATIC NEOPLASMS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84875162527     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000348527     Document Type: Article

References (9)

1. Rhim AD, Mirek ET, Aiello NM, et al.: EMT and dissemination precede pancreatic tumor formation. Cell 2012;148:249-361.
2. Haeno H, Gonen M, Davis MB, et al.: Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 2012;148:362-375.
3. Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al.: Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7:e1000267.
4. Evans DB, Rich TA, Byrd DR, et al.: Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992; 127:1335-1339.
5. Morganti AG, Massaccesi M, La Torre G, et al.: A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol 2010;17: 194-205.
6. Conroy T, Desseigne F, Ychou M, et al.: FOLFIRI-NOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-1825.
7. Von Hoff DD, Ramanathan RK, Borad MJ, et al.: Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial. J Clin Oncol 2011;29:4548-4554.
8. Desai N, Trieu V, Yao Z, et al.: Increased antitumor activity, intratumoral paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-1324.
9. Boeck S, Haas M, Laubender RP, et al.: Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer. Clin Cancer Res 2010; 16:986-994.